H.R.733 - Recalcitrant Cancer Research Act of 2012112th Congress (2011-2012)
|Sponsor:||Rep. Eshoo, Anna G. [D-CA-14] (Introduced 02/16/2011)|
|Committees:||House - Energy and Commerce|
|Latest Action:||09/20/2012 Received in the Senate.|
This bill has the status Passed House
Here are the steps for Status of Legislation:
- Passed House
Summary: H.R.733 — 112th Congress (2011-2012)All Bill Information (Except Text)
Passed House amended (09/19/2012)
Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years.
Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year. Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer.
Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act.
Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.